Database/Test-Folke2-Layout

Folke2 test layout

This is a test page for experimenting with the presentation layout of Folke2 interactions

Raw data

{'approval_date': u'2009-12-28',
 'classification': {'documentation_class': u'1',
                    'id': u'15942',
                    'severity_class': u'C'},
 'id': u'15942',
 'publishing_date': u'2009-12-28',
 'reference_ids': [],
 'section': {'content': u'F\xf6rsiktighet rekommenderas vid samtidig administrering av cilostazol med n\xe5got annat l\xe4kemedel som inhiberar trombocytaggregeringen. Bl\xf6dningstiderna b\xf6r bevakas med j\xe4mna intervall. S\xe4rskild uppm\xe4rksamhet b\xf6r \xe4gnas patienter som f\xe5r multipla antitrombocytbehandlingar.',
             'id': u'14582',
             'inter_section_type_lx': u'1',
             'language': u'sv'},
 'substance_1': {'casno': u'143653-53-6',
                 'parent_cas_no': u'143653-53-6',
                 'parent_substance_id': u'IDE4POI9UCA6KVERT1',
                 'parent_substance_name': u'abciximab',
                 'substance_id': u'IDE4POI9UCA6KVERT1',
                 'substance_name': u'abciximab'},
 'substance_2': {'casno': u'73963-72-1',
                 'parent_cas_no': u'73963-72-1',
                 'parent_substance_id': u'IDE4POFEUAXGOVERT1',
                 'parent_substance_name': u'cilostazol',
                 'substance_id': u'IDE4POFEUAXGOVERT1',
                 'substance_name': u'cilostazol'}}

Presentation layout

abciximab - cilostazol15942